JAMP ALPRAZOLAM TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
12-08-2021
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ALPRAZOLAM
Inapatikana kutoka:
JAMP PHARMA CORPORATION
ATC kanuni:
N05BA12
INN (Jina la Kimataifa):
ALPRAZOLAM
Kipimo:
1MG
Dawa fomu:
TABLET
Tungo:
ALPRAZOLAM 1MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100/500/1000
Dawa ya aina:
Targeted (CDSA IV)
Eneo la matibabu:
BENZODIAZEPINES
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0115008003; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2020-09-15
Tabia za bidhaa
JAMP-Alprazolam (alprazolam)-Product Monograph Page 1 of 43
PRODUCT MONOGRAPH JAMP ALPRAZOLAM
Alprazolam Tablets, USP
0.25 mg, 0.5 mg, 1 mg and 2 mg
ANXIOLYTIC
– ANTIPANIC
JAMP Pharma Corporation Date of Revision:
1310 rue Nobel August 12, 2021
Boucherville,
Quebec
J4B 5H3
Submission
Control No.: 253380
JAMP-Alprazolam (alprazolam)-Product Monograph Page 2 of 43
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
............................................................................
3
CONTRAINDICATIONS
..............................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
5
ADVERSE REACTIONS
.............................................................................................
13
DRUG INTERACTIONS
.............................................................................................
17
DOSAGE AND ADMINISTRATION
............................................................................
20
OVERDOSAGE
.........................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 23
STORAGE AND STABILITY
......................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 24
PART II: SCIENTIFIC INFORMATION
................................................................. 26
PHARMACEUTICAL INFORMATION
........................................................................
26
CLINICAL TRIALS
....................................................................................................
26
DETAILED PHARMACOLOGY
........................................
Soma hati kamili
